Surfactin C inhibits platelet aggregation

• Published in: Journal of pharmacy and pharmacology 2006-06, Vol.58 (6), p.867-870
• Main Authors: Kim, Sung Dae, Park, Sun Kyu, Cho, Jae Youl, Park, Hwa Jin, Lim, Jong Hwan, Yun, Hyo In, Park, Seung Chun, Lee, Kyoung Youl, Kim, Sang Keun, Rhee, Man Hee
• Format: Article
• Language: English
• Subjects: Animals; Calcium - metabolism; Collagen - pharmacology; Dose-Response Relationship, Drug; Lipopeptides; Peptides, Cyclic - pharmacology; Phospholipases A - physiology; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - pharmacology; Rats; Thrombin - pharmacology
• ISSN: 0022-3573; 2042-7158
• DOI: 10.1211/jpp.58.6.0018

This study was designed to investigate the effect of surfactin C, which is derived from Bacillus subtilis, on platelet aggregation and homotypic leucocyte aggregation. Surfactin C strongly and dose‐dependently inhibited platelet aggregation, which was stimulated both by thrombin (0.1 U mL−1), a potent agonist that activates the G protein‐coupled protease receptor, and by collagen (5 μg mL−1), a potent ligand that activates αIIbβ3 with IC50 values (concentration inhibiting platelet aggregation by 50%) of 10.9 and 17.0 μM, respectively. Moreover, surfactin C significantly suppressed the intracellular Ca2+ mobilization in thrombin‐activated platelets. Surfactin C, however, did not affect various integrin‐mediated U937 cell aggregation, implying that the anti‐platelet activity of surfactin C was not due to its detergent effect but by its action on the downstream signalling pathway. Therefore, the results suggest that surfactin C may have a beneficial therapeutic effect on aberrant platelet aggregation‐mediated cardiovascular diseases.